Allarity Therapeutics Inc
Change company Symbol lookup
Select an option...
ALLR Allarity Therapeutics Inc
SIVB SVB Financial Group
LYLT Loyalty Ventures Inc
NMRD Nemaura Medical Inc
LOGI Logitech International SA
BIOC Biocept Inc
KT KT Corp
SVRA Savara Inc
KA Kineta Inc
IMNM Immunome Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company. The Company is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The Company's products include dovitinib, stenoparib, and IXEMPRA (ixabepilone). The lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. The therapeutic candidate is stenoparib is a novel inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). The therapeutic candidate is IXEMPRA (ixabepilone) is a selective microtubule inhibitor. The DRP technology is a diagnostic platform that models human tumor biology and can help predict whether a cancer patient respond or not to a particular drug.

Closing Price
$0.1439
Day's Change
0.0389 (37.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.229
Day's Low
0.1301
Volume
(Heavy Day)
Volume:
83,434,571

10-day average volume:
8,156,624
83,434,571

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Olaplex Holdings, Inc. Investors With Losses to Secure Counsel Before Important January 17 Deadline in Securities Class Action - OLPX

7:50 pm ET January 15, 2023 (Newsfile) Print

New York, New York--(Newsfile Corp. - January 15, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Olaplex Holdings, Inc. (NASDAQ: OLPX) pursuant and/or traceable to the Company's initial public offering conducted in September 2021 (the "IPO"), of the important January 17, 2023lead plaintiff deadline.

SO WHAT: If you purchased Olaplex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Olaplex class action, go to https://rosenlegal.com/submit-form/?case_id=10056 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the registration statement and prospectus used to effectuate Olaplex's IPO contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and was not prepared in accordance with the rules and regulations governing its preparation. Specifically, the offering documents made false and/or misleading statements and/or failed to disclose that: (1) macro-economic pressures and competition in the haircare market were more robust than Olaplex had represented to investors; (2) accordingly, Olaplex was unlikely to maintain its sales and revenue momentum; (3) as a result, it was unlikely that Olaplex would be able to achieve the financial and operational growth projected in the offering documents; and (4) as a result, the offering documents were materially false and/or misleading and failed to state information required to be stated therein.

To join the Olaplex class action, go to https://rosenlegal.com/submit-form/?case_id=10056 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

lrosen@rosenlegal.com

pkim@rosenlegal.com

cases@rosenlegal.com

www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/151377

comtex tracking

COMTEX_422731350/2523/2023-01-15T19:50:23

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.